Interferon gamma (IFN-γ) is a dimeric soluble cytokine and the only type II interferon. Accumulated evidence suggests that IFN-γ inhibits tumor progression. This study investigated the effects of IFN-γ on the proliferation and migration of pancreatic cancer (PC) cells and the underlying mechanism. IFN-γ treatment decreased the expression and secretion of CXCL8 in BxPC-3 PC cells, suppressed the proliferation and migration of these cells, and enhanced their apoptosis, as determined by increased levels of cleaved Caspase-8 and Bax together with reduced expression of Bcl-2. These effects were abolished by overexpression of CXCL8. Moreover, IFN-γ treatment downregulated RhoGDI2 expression. Depletion of RhoGDI2 and Rac1 by using small interfering RNAs and inhibition of NF-κB by BMS-345541 (an IκB kinase [IKK] inhibitor) suppressed expression of CXCL8. Our results indicate that IFN-γ inhibits the proliferation and migration of PC cells by suppressing CXCL8 expression via a RhoGDI2/Rac1/NF-κB signaling pathway.
Get full access to this article
View all access options for this article.
References
1.
BachEA, AguetM, SchreiberRD. 1997. The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol, 15:563–591.
BlankensteinT, QinZ. 2003. The role of IFN-gamma in tumor transplantation immunity and inhibition of chemical carcinogenesis. Curr Opin Immunol, 15(2):148–154.
4.
BratDJ, BellailAC, Van MeirEG. 2005. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol, 7(2):122–133.
5.
ChenWQ, ZhengRS, BaadePD, ZhangSW, ZengHM, BrayF, JemalA, YuXQ, HeJ. 2016. Cancer statistics in China, 2015. CA Cancer J Clin, 66(2):115–132.
6.
DetjenKM, FarwigK, WelzelM, WiedenmannB, RosewiczS. 2001. Interferon gamma inhibits growth of human pancreatic carcinoma cells via caspase-1 dependent induction of apoptosis. Gut, 49(2):251–262.
7.
EalickSE, CookWJ, Vijay-KumarS, CarsonM, NagabhushanTL, TrottaPP, BuggCE. 1991. Three-dimensional structure of recombinant human interferon-gamma. Science, 252(5006):698–702.
8.
FarrarMA, SchreiberRD. 1993. The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol, 11:571–611.
9.
GeorgeJ, BanikNL, RaySK. 2010. Knockdown of hTERT and concurrent treatment with interferon-gamma inhibited proliferation and invasion of human glioblastoma cell lines. Int J Biochem Cell Biol, 42(7):1164–1173.
10.
GrinerEM, TheodorescuD. 2012. The faces and friends of RhoGDI2. Cancer Metastasis Rev, 31(3–4):519–528.
11.
HolmesWE, LeeJ, KuangWJ, RiceGC, WoodWI. 2009. Structure and functional expression of a human interleukin-8 receptor. Science 1991. 253: 1278–1280. J Immunol, 183(5):2895–2897.
12.
IkedaH, OldLJ, SchreiberRD. 2002. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev, 13(2):95–109.
LiMQ, LuoXZ, MengYH, MeiJ, ZhuXY, JinLP, LiDJ. 2012. CXCL8 enhances proliferation and growth and reduces apoptosis in endometrial stromal cells in an autocrine manner via a CXCR1-triggered PTEN/AKT signal pathway. Hum Reprod, 27(7):2107–2116.
15.
LongKB, GladneyWL, TookerGM, GrahamK, FraiettaJA, BeattyGL. 2016. IFNgamma and CCL2 cooperate to redirect tumor-infiltrating monocytes to degrade fibrosis and enhance chemotherapy efficacy in pancreatic carcinoma. Cancer Discov, 6(4):400–413.
SchoenbornJR, WilsonCB. 2007. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol, 96:41–101.
22.
ShibuyaKC, GoelVK, XiongW, ShamJG, PollackSM, LeahyAM, WhitingSH, YehMM, YeeC, RiddellSR, PillarisettyVG. 2014. Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment. PLoS One, 9(5):e96565.
23.
SiegelRL, MillerKD, JemalA. 2016. Cancer statistics, 2016. CA Cancer J Clin, 66(1):7–30.
24.
SiegelRL, MillerKD, JemalA. 2017. Cancer Statistics, 2017. CA Cancer J Clin, 67(1):7–30.
25.
WangXY, CrowstonJG, WhiteAJR, ZoellnerH, HealeyPR. 2014. Interferon-alpha and interferon-gamma modulate Fas-mediated apoptosis in mitomycin-C-resistant human Tenon's fibroblasts. Clin Exp Ophthalmol, 42(6):529–538.
26.
WaughDJ, WilsonC. 2008. The interleukin-8 pathway in cancer. Clin Cancer Res, 14(21):6735–6741.
27.
WolfgangCL, HermanJM, LaheruDA, KleinAP, ErdekMA, FishmanEK, HrubanRH. 2013. Recent progress in pancreatic cancer. CA Cancer J Clin, 63(5):318–348.
28.
XieFJ, ZhaoP, ZhangYP, LiuFY, NieXL, ZhuYH, YuXM, ZhengQQ, MaoWM, LuHY, WeiH, HuangW. 2013. Adenovirus-mediated interferon-gamma gene therapy induced human pancreatic carcinoma Capan-2 cell apoptosis in vitro and in vivo. Anat Rec (Hoboken), 296(4):604–610.
29.
YiB, HuY, QinG, GuW, ZhuX, HeS, ZhouJ, LiD. 2014. Depletion of RhoGDI2 expression inhibits the ability of invasion and migration in pancreatic carcinoma. Int J Mol Med, 34(1):205–212.
30.
YiB, ZhangY, ZhuD, ZhangL, SongS, HeS, ZhangB, LiD, ZhouJ. 2015. Overexpression of RhoGDI2 correlates with the progression and prognosis of pancreatic carcinoma. Oncol Rep, 33(3):1201–1206.
31.
YoungHA, HardyKJ. 1995. Role of interferon-gamma in immune cell regulation. J Leukoc Biol, 58(4):373–381.
32.
ZaidiMR, MerlinoG. 2011. The two faces of interferon-gamma in cancer. Clin Cancer Res, 17(19):6118–6124.
33.
ZhaoYH, WangT, YuGF, ZhuangDM, ZhangZ, ZhangHX, ZhaoDP, YuAL. 2013. Anti-proliferation effects of interferon-gamma on gastric cancer cells. Asian Pac J Cancer Prev, 14(9):5513–5518.
34.
ZoonKC. 1987. Human interferons: structure and function. Interferon, 9:1–12.
